The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors
Author:
Publisher
Elsevier BV
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,Molecular Medicine,Biochemistry
Reference54 articles.
1. In vivo vizualisation of mono-ADP-ribosylation by dPARP16 upon amino-acid starvation;Aguilera-Gomez;Elife,2016
2. Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors;Antolin;Oncotarget,2014
3. Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone;Aoyagi-Scharber;Acta Crystallogr. F Struct. Biol. Commun.,2014
4. The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation;Bolin;Cell. Mol. Life Sci.,2012
5. Regulation of mitochondrial poly(ADP-Ribose) polymerase activation by the beta-adrenoceptor/cAMP/protein kinase A axis during oxidative stress;Brunyanszki;Mol. Pharmacol.,2014
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A Tandem-Affinity Purification Method for Identification of Primary Intracellular Drug-Binding Proteins;ACS Chemical Biology;2024-01-25
2. Death by a thousand cuts through kinase inhibitor combinations that maximize selectivity and enable rational multitargeting;eLife;2023-12-04
3. Integration of Thermal Proteome Profiling with phosphoproteomic and transcriptomic data via mechanistic network models decodes the molecular response to PARP inhibition;2023-08-16
4. Unravelling the Role of PARP1 in Homeostasis and Tumorigenesis: Implications for Anti-Cancer Therapies and Overcoming Resistance;Cells;2023-07-21
5. NAD+ Consuming Enzymes: Involvement in Therapies and Prevention of Human Diseases;Anti-Cancer Agents in Medicinal Chemistry;2023-07-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3